Boston, MA, September 24, 2016 --(PR.com
)-- Gene editing broadly refers to a suite of methods that use programmable endonuclease to target a specific site in the genome that can induce double stranded break (DSB) which are then repaired by disrupting or modifying the target sequence. There are four major classes of gene editing technologies, including meganuclease and their derivatives, Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), and Clustered Regularly Interspaced Short Palindromic (CRISPR)-associated nuclease Cas9. These nucleases can be broadly divided into two classes based on their mode of DNA recognition; ZFN, TALEN and meganucleases bind to DNA via protein-DNA interaction, whereas Cas9 binds to DNA with a short guide RNA (g RNA) by Watson-Crick base-pairing. Moreover, transposons are used as gene editing tools that can integrate desired genes into the host genome by using their inherent ‘cut and paste’ process. As per IQ4I estimates, the overall genome-editing market is expected to reach $2,669.9 million by 2022.
Increased R&D expenditure and growth of biotechnology and pharmaceutical industries, increasing private and public sector funding, rapid advancements in sequencing and gene editing technologies, non-labeling of gene edited products as Genetically Modified Organisms (GMOs), applications in various drug discovery processes and are some of the factors driving the genome editing global market growth. Factors such as stringent regulatory framework, ethical issues concerning editing human embryo and adverse public perception, unavailability of gene-editing based therapeutics in market, off-target effects of CRISPR and patent disputes associated with CRISPR technology are hampering the market growth.
The global genome editing market, based on technology type is segmented into ZFN, TALEN, CRISPR and Others. CRISPR held the largest market share of and is expected to grow at a high double digit CAGR from 2015 to 2022.
Based on application genome editing market is classified into basic research, agriculture/plant biotechnology, animal biotechnology and drug discovery & development. Basic research accounted for largest share of and is expected to grow at a high CAGR from 2015 to 2022. Drug discovery and development is further segmented into pre-clincal and clinical.
The global genome market by products and services is segmented into reagents, enzymes and consumables, cell lines and animal models, genome editing services, instruments and software. Reagents, enzymes and consumables accounted for largest share and is expected to grow at double digit CAGR from 2015 to 2022.
Genome editing end users market is segmented into academic and government institutions, Plant biotechnology companies, pharmaceutical and biotechnology companies and others that include animal biotechnology and contract research organizations (CRO). Academic and government institutes accounted for largest share of is expected to grow at double digit CAGR from 2015 to 2022.
Some of the major companies in the genome editing market are Applied Stemcell (U.S.), Cellectis S.A. (France), Genscript (U.S.), Horizon Discovery Group (U.K.), Merck KGaA (Germany), Origene Technologies (U.S.), Sangamo Biosciences (U.S.), System Biosciences (U.S.), Thermo Fisher Scientific (U,S,) and Transposagen BioPharmaceuticals (U.S.).Other companies include GE Healthcare (U.K.), Agilent Technologies (U.S.) New England Biolabs (NEB) (U.S.), Integrated DNA Technologies (IDT) (U.S.), Lonza (Switzerland), Addgene (U.S.), Precision Biosciences (U.S.), Bluebird Bio (U.S.), Editas Medicine (U.S.), Caribou Bioscience (U.S.), CRISPR Therapeutics (Switzerland), ERS Genomics (Ireland) and Takara Bio (Japan).